Suppr超能文献

锌指核酸酶敲除人肿瘤细胞系中的 NADPH:细胞色素 P450 氧化还原酶 (POR) 表明缺氧激活前药在 POR 依赖性方面存在差异。

Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.

机构信息

From the Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.

出版信息

J Biol Chem. 2013 Dec 27;288(52):37138-53. doi: 10.1074/jbc.M113.505222. Epub 2013 Nov 6.

Abstract

Hypoxia, a ubiquitous feature of tumors, can be exploited by hypoxia-activated prodrugs (HAP) that are substrates for one-electron reduction in the absence of oxygen. NADPH:cytochrome P450 oxidoreductase (POR) is considered one of the major enzymes responsible, based on studies using purified enzyme or forced overexpression in cell lines. To examine the role of POR in HAP activation at endogenous levels of expression, POR knock-outs were generated in HCT116 and SiHa cells by targeted mutation of exon 8 using zinc finger nucleases. Absolute quantitation by proteotypic peptide mass spectrometry of DNA sequence-confirmed multiallelic mutants demonstrated expression of proteins with residual one-electron reductase activity in some clones and identified two (Hko2 from HCT116 and S2ko1 from SiHa) that were functionally null by multiple criteria. Sensitivities of the clones to 11 HAP (six nitroaromatics, three benzotriazine N-oxides, and two quinones) were compared with wild-type and POR-overexpressing cells. All except the quinones were potentiated by POR overexpression. Knocking out POR had a marked effect on antiproliferative activity of the 5-nitroquinoline SN24349 in both genetic backgrounds after anoxic exposure but little or no effect on activity of most other HAP, including the clinical stage 2-nitroimidazole mustard TH-302, dinitrobenzamide mustard PR-104A, and benzotriazine N-oxide SN30000. Clonogenic cell killing and reductive metabolism of PR-104A and SN30000 under anoxia also showed little change in the POR knock-outs. Thus, although POR expression is a potential biomarker of sensitivity to some HAP, identification of other one-electron reductases responsible for HAP activation is needed for their rational clinical development.

摘要

缺氧是肿瘤的普遍特征,可以被缺氧激活的前药(HAP)利用,这些前药是在没有氧气的情况下通过单电子还原的底物。基于使用纯化酶或在细胞系中强制过表达的研究,NADPH:细胞色素 P450 氧化还原酶(POR)被认为是主要负责的酶之一。为了在表达的内源性水平检查 POR 在 HAP 激活中的作用,使用锌指核酸酶靶向突变外显子 8 在 HCT116 和 SiHa 细胞中生成 POR 敲除体。通过 DNA 序列确证的多等位基因突变体的蛋白质特征肽质量谱绝对定量证明了一些克隆中具有残留单电子还原酶活性的蛋白质的表达,并通过多种标准鉴定了两个(来自 HCT116 的 Hko2 和来自 SiHa 的 S2ko1)功能缺失。用 11 种 HAP(6 种硝基芳烃、3 种苯并三嗪 N-氧化物和 2 种醌)比较了克隆的敏感性与野生型和 POR 过表达细胞。除了醌之外,所有这些都通过 POR 过表达增强。在缺氧暴露后,在两种遗传背景下,敲除 POR 对 5-硝基喹啉 SN24349 的抗增殖活性有明显影响,但对大多数其他 HAP 的活性几乎没有影响,包括临床阶段的 2-硝基咪唑烷 TH-302、二硝基苯甲酰胺 PR-104A 和苯并三嗪 N-氧化物 SN30000。在缺氧条件下,PR-104A 和 SN30000 的克隆形成细胞杀伤和还原代谢也显示 POR 敲除体的变化很小。因此,尽管 POR 表达是对一些 HAP 敏感的潜在生物标志物,但需要鉴定其他单电子还原剂来负责 HAP 的激活,以实现其合理的临床开发。

相似文献

2
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
Cancer Res. 2015 Oct 1;75(19):4211-23. doi: 10.1158/0008-5472.CAN-15-1107. Epub 2015 Aug 21.
3
Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
Mol Pharmacol. 2012 Jan;81(1):31-40. doi: 10.1124/mol.111.073759. Epub 2011 Oct 7.
4
The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
Biochem Pharmacol. 2014 May 15;89(2):224-35. doi: 10.1016/j.bcp.2014.03.001. Epub 2014 Mar 13.
6
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.
Biochem Pharmacol. 2014 Oct 15;91(4):436-46. doi: 10.1016/j.bcp.2014.08.003. Epub 2014 Aug 15.
9
The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
Clin Cancer Res. 2012 Mar 15;18(6):1684-95. doi: 10.1158/1078-0432.CCR-11-2296. Epub 2011 Dec 13.
10
Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.
Mol Cancer Ther. 2009 Jun;8(6):1714-23. doi: 10.1158/1535-7163.MCT-08-1209. Epub 2009 Jun 9.

引用本文的文献

1
Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisation.
RSC Med Chem. 2023 Jun 8;14(7):1309-1330. doi: 10.1039/d3md00117b. eCollection 2023 Jul 20.
2
Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling.
Front Pharmacol. 2022 Feb 8;13:803602. doi: 10.3389/fphar.2022.803602. eCollection 2022.
3
Therapeutic targeting of the hypoxic tumour microenvironment.
Nat Rev Clin Oncol. 2021 Dec;18(12):751-772. doi: 10.1038/s41571-021-00539-4. Epub 2021 Jul 29.
4
Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
Cancer Chemother Pharmacol. 2021 Oct;88(4):673-687. doi: 10.1007/s00280-021-04320-3. Epub 2021 Jul 10.
7
Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors.
Molecules. 2019 Jul 10;24(14):2524. doi: 10.3390/molecules24142524.
8
Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.
Front Pharmacol. 2018 Sep 18;9:1013. doi: 10.3389/fphar.2018.01013. eCollection 2018.
10
The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
Oncotarget. 2017 Apr 4;8(14):23702-23712. doi: 10.18632/oncotarget.15784.

本文引用的文献

2
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.
Trends Biotechnol. 2013 Jul;31(7):397-405. doi: 10.1016/j.tibtech.2013.04.004. Epub 2013 May 9.
3
Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system.
Mol Pharmacol. 2013 Jun;83(6):1209-17. doi: 10.1124/mol.112.084616. Epub 2013 Mar 25.
4
6
NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology.
Drug Metab Dispos. 2013 Jan;41(1):12-23. doi: 10.1124/dmd.112.048991. Epub 2012 Oct 19.
7
Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.
J Urol. 2012 Apr;187(4):1195-9. doi: 10.1016/j.juro.2011.11.101. Epub 2012 Feb 14.
9
The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
Clin Cancer Res. 2012 Mar 15;18(6):1684-95. doi: 10.1158/1078-0432.CCR-11-2296. Epub 2011 Dec 13.
10
Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
Mol Cancer Ther. 2012 Mar;11(3):740-51. doi: 10.1158/1535-7163.MCT-11-0634. Epub 2011 Dec 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验